All In Biotech

Drug Trial Radar · NCT05032820

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMTCTN1902

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Jan 5, 2022

Primary completion

Aug 22, 2024

Study completion Feb 20, 2025

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program; Celgene a wholly owned subsidiary of BMS
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).

Conditions

  • Multiple Myeloma

Interventions

  • LenalidomideDrug

    Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression

  • bb2121Biological

    Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\^6 cells.

  • CyclophosphamideDrug

    300 mg/m\^2/day for 3 consecutive days prior to the CAR T infusion

  • FludarabineDrug

    30 mg/m\^2/day or 3 consecutive days prior to the CAR T infusion

  • leukapheresisProcedure

    Placement of central line catheter and leukapheresis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of BCMA CAR-T Cell TherapyTime frame: 6 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Stanford Hospital and Clinics

    Palo Alto, California

  • University of California, San Francisco

    San Francisco, California

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Roswell Park Cancer Center

    Buffalo, New York

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Pennsylvania Hospital Center

    Philadelphia, Pennsylvania

  • Baylor College and Medicine

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • University of Wisconsin Hospitals and Clinics

    Madison, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.